European biotechs Morphosys and Galapagos have handed over their joint atopical dermatitis programme MOR106 to Novartis for up to €945m. The Swiss pharma giant aims to strengthen its commitment to lead immuno-dermatology, the company said.
The Innovative Medicines Initiative has launched a new Antimicrobial Resistance Accelerator Programme after Novartis announced its retreat from antibiotics research only days ago.
Roche announced today that the US-American Food and Drug Administration FDA has granted Breakthrough Therapy designation for the Swiss pharma giants mAb combination therapy for liver cancer.
UK biotech Oxford BioDynamics has presented data showing that the companys blood test can predict patient response to treatment with immune checkpoint inhibitors anti-PD-1 and anti-PD-L1.
It was too good to be true. Following harsh criticism from industry, the European Patent Office (EPO) drafted a widely applauded proposal to allow exemptions to its Early Certainty Initiative in Examination. One month later, the EPO withdrew UDEC following a recommendation from Business Europe – the only business association sitting next to decision-makers in the EPOs Administrative Council – not to bring UDEC into force in July.
Swiss biopharma company Urovant Sciences has launched its IPO on Nasdaq, seeking US$150m. The proceeds will go to Phase III trials for its overactive bladder treatment candidate vibegron.
Independent investment analyst, Managing Director EQUI.TS GmbH_ Big data analytics is poised to change the way business is done in the life sciences. A string of recent M&A transactions illustrate this trend.
Danish Genmab and German Immatics Biotechnologies are collaborating to discover and develop next-generation bispecific immunotherapies to develop therapeutics in multiple cancer indications.
Using only openly available genomic data, researchers in Barcelona have developed a new method to systematically identify genes contributing to heritable cancer risk.
Norwegian diabetes expert Lifecare AS has gone public on the Oslo stock exchange. The sensor maker plans to fund the next phase of development for its implantable glucose sensor.